Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies-MedSci.cn

Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies

Wu, YL; Smit, EF; Bauer, TM

Wu, YL (corresponding author), Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangdong Prov Key Lab Translat Med Lung Canc, 106 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China.

CANCER TREATMENT REVIEWS, 2021; 95 ():

Abstract

The mesenchymal-epithelial transition (MET) receptor tyrosine kinase binds the hepatocyte growth factor to activate downstream cell signaling pathways......

Full Text Link